GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2009

Hydra and Cubist Ally to Further Ion Channel Drugs for Pain Management

  • Cubist Pharmaceuticals is paying $5 million up front to collaborate with Hydra Biosciences on the development of ion channel drugs for pain management. Cubist will support Hydra’s internal development R&D programs with another $5 million over two years.

    Hydra’s focus has been on compounds that target the TRPA1 receptor, which is believed to have an important role in pain management. The partnership will build on existing preclinical data and pharmacology studies.

    Under the terms of the agreement, Hydra is eligible for development milestones and royalties on product sales.

     

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?